Cannabinodiol was first isolated and characterised in the early 1970s. Its structure is formally a fully conjugated analogue of cannabidiol (CBD), differing in that both the terpenoid and phenolic rings are aromatic , a feature that makes CBND among the more oxidised cannabinoids detected in aged or degraded plant material. It is considered a minor cannabinoid; concentrations reported in raw plant extracts are generally at or below the threshold of reliable quantification by standard HPLC methods.
The biosynthetic origin of CBND in the plant is not firmly established. The prevailing hypothesis is that it arises through progressive oxidative aromatisation of CBD or related precursors during drying, prolonged storage, or UV exposure, rather than through a dedicated enzymatic pathway. This places CBND in a similar category to cannabinol (CBN) , a degradation or transformation product rather than a primary biosynthetic target.
Receptor interaction data for CBND are sparse. Published binding studies are limited in number and scope; the available evidence does not establish a well-characterised affinity profile at CB1 or CB2 receptors comparable to that documented for major cannabinoids such as THC or CBD. No significant activity at either receptor subtype has been conclusively demonstrated at physiologically relevant concentrations in peer-reviewed literature to date. Research into its pharmacological profile remains at an early, largely descriptive stage.
CBND is not listed as a controlled substance under the Australian Poisons Standard (the Standard for the Uniform Scheduling of Medicines and Poisons) in its own right; however, preparations derived from Cannabis sativa are subject to scheduling based on their overall cannabinoid composition and origin. Researchers working with cannabis-derived extracts containing CBND in Australia must comply with the relevant Schedule 8 or Schedule 9 provisions of the Poisons Standard and any applicable state and territory legislation.
Sources: